HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Halozyme Therapeutics, maintaining a price target of $65. Analyst Mitchell Kapoor continues to see potential in the company's stock.
September 16, 2024 | 10:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Halozyme Therapeutics, maintaining a price target of $65. Analyst Mitchell Kapoor continues to see potential in the company's stock.
The reiteration of a Buy rating and maintenance of a $65 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100